厄贝沙坦对高血压并阵发性房颤患者房颤复发的影响

Effects of Irbesartan on Recurrence of Atrial Fibrillation in Patients With Hypertension Complicating Paroxysmal Atrial Fibrillation

目的:评价厄贝沙坦对高血压并发阵发性房颤(PAF)患者的抗心律失常效应。方法:选取99例高血压并发PAF患者,分成厄贝沙坦治疗组(A组)49例和氨氯地平治疗组(B组)50例,在口服胺碘酮的基础上分别加用厄贝沙坦、氨氯地平治疗12个月。比较2组治疗后第3、6、12个月房颤复发率和治疗后第6、12个月的左心房内径(LAD)。结果:2组均能显著降低血压。治疗后第3、6个月,2组的房颤复发率无显著差异(P>0.05);治疗后第12个月2组房颤复发率分别为20.8%和41.7%,差异有统计学意义(P<0.05)。治疗后第12个月A组LAD小于B组(P<0.05)。结论:厄贝沙坦能延缓高血压并发PAF患者的左心房扩大,并明显降低房颤复发率。

Objective：To evaluate the anti-fibrillatory effects of valsartan in patients with hypertension complicating paroxysmal atrial fibrillation（PAF）.Methods：A total of 99 patients with hypertension complicating PAF were randomly assigned to receive either irbesartan combined with amiodarone（group A,n = 49） or amlodipine combined with amiodarone（group B,n =50）.The recurrence rate of atrial fibrillation（AF） was measured at the 3rd,6th and 12th month after treatments,and the left atrial diameter（LAD） was measured at the 6th and 12th month after treatments.Results：Both Irbesartan and amlodipine significantly reduced blood pressure to a similar degree.There was no difference in recurrence rate of AF between two groups at the 3rd and 6th month（P 0.05）.The recurrence rate of AF in group A and group B were 20.8% and 41.7% at the 12th month after treatments respectively（P 0.05）.LAD in group B was significantly larger than that of group A at the 12th month after treatments（P 0.05）.Conclusion：Irbesartan can obviously delay the enlargement of the left atrium and decrease the recurrence rate of AF in patients with hypertension complicating PAF.